Australian Injectable Drugs Handbook: 9th Edition updates

The Australian Injectable Drugs Handbook provides up-to-date and vital information on more than 500 injectable medicines and is an essential frontline resource ensuring patient safety and quality care.

Updated information and new monographs from the ninth edition can be found here.

Important new or changed information affecting administration,  stability or compatibility. We recommend printing and replacing these pages in your hard copy of  AIDH 9.





These new medicine monographs are added to AIDH 9 online. These monographs are not included in the print copy of AIDH 9, including reprints. 

Andexanet alfa






December 2023

New drugs andexanet alfa, difelikefalin, dostarlimab, faricimab, lenacapavir, and vosoritide

Updated availability information for carboprost, daptomycin, and pemetrexed

Medicine shortages availability advice for dipyridamole, fludarabine, and mycobacterium bovis

Updated stability information for chorionic gonadotropin, dacarbazine, fulvestrant, natalizumab, and omalizumab

New compatibility information for oxycodone (Hartmann’s)

Addition of infusion equipment requirements for plitidepsin

Clarification of diluent for sodium valproate in status epilepticus

Clarification of soy as source of lecithin in benzathine benzylpenicillin (Bicillin-LA)

Updates to imipenem-cilastatin, and isavuconazole in response to user feedback

Summary of medicines requiring non-PVC and/or DEHP-free containers and infusion sets.

September 2023

Aciclovir (addition of powder presentation)

Phenylephrine (addition of Accord brand)

Aciclovir (addition of powder presentation)

Benzathine benzylpenicillin (clarification of soy as source of lecithin)

Carboprost (addition of Australian-registered products)

Chorionic gonadotropin (updated stability)

Dacarbazine (updated stability)

Daptomycin (addition of Lupin, Pfizer products)

Dipyridamole (addition of S19A products)

Fludarabine (addition of S19A products)

Fulvestrant (updated stability)

Imipenem-cilastatin (updated concentration range)

Isavuconazole (addition of prodrug equivalence information)

Mycobacterium bovis (addition of S19A products)

Natalizumab (updated stability)

Omalizumab (updated stability)

Oxycodone (updated compatibility and stability)

Pemetrexed (addition of concentrated solution presentation)

Phenylephrine (addition of Accord brand)

Plitidepsin (clarification of container and infusion-set requirements)

Sodium valproate (updated compatibility)